Glenmark Pharmaceuticals has set an ambitious revenue target of ₹17,000-18,000 crore for the fiscal year 2027, anticipating robust growth fueled by strategic initiatives and market expansion. The pharmaceutical major also projects an EBITDA margin of 21-22% for the same period, signaling confidence in its operational efficiency and future profitability.
Strategic Pillars for Growth
The company's growth strategy centers on strengthening its portfolio in branded medicines, respiratory products, and oncology therapies. These segments are expected to be key contributors to performance across its diverse geographic footprint, including India, the United States, Europe, and emerging markets.
"With infrastructure now in place across all markets, we expect broad-based growth," stated Anurag Mantri, Executive Director and Global Chief Financial Officer of Glenmark Pharmaceuticals.
Glenmark is specifically targeting branded products to account for 70% of its total revenue by 2030, a significant increase from the current 60%. This shift underscores a focus on higher-margin, proprietary products.
Global Market Expansion and Product Launches
The drugmaker's international expansion is a critical component of its growth strategy. In the past fiscal year, Glenmark cemented a licensing agreement with AbbVie for ISB 2001, an investigational oncology asset, involving an upfront payment of $700 million and potential milestone payments up to $1.925 billion. Glenmark retains commercialization rights for this asset in emerging markets.
Key Market Highlights:
- Emerging Markets: A key focus area, with planned launches of Aumolertinib and Trastuzumab Rezetecan. These markets, spanning the Middle East, Africa, LATAM, Asia-Pacific, Russia, and CIS countries, are expected to play a crucial role in the branded revenue shift.
- United States: Performance is anticipated to be driven by respiratory medicines and injectables. The company received approvals for generic Flovent HFA 44 mcg and Fluticasone Propionate Nasal Spray OTC, which were commercialized recently. The Monroe facility also secured a US FDA Establishment Inspection Report, allowing for resumed commercial manufacturing.
- Europe: The launch of Winlevi in the UK and its subsequent EU approval during FY26 are set to establish Glenmark's branded dermatology presence in the region.
- India: The domestic business grew 1.5 times faster than the Indian Pharmaceutical Market during FY26, ranking as the second-fastest-growing among the top 15 pharma companies. New launches included Tevimbra and Brukinsa in oncology, Nebzmart GFB Smartules and Glenmark Airz FB Smartules in respiratory care, and Glipiq for diabetes.
Glenmark's flagship product, Ryaltris, is now marketed in over 50 countries and recorded more than 50% growth in secondary sales in commercial markets during FY26. The company anticipates Ryaltris to eventually generate annual sales exceeding $200 million.
Financial Health and Future Investments
For FY26, Glenmark reported a consolidated revenue of ₹16,982.5 crore, marking a 27.5% year-on-year increase. EBITDA stood at ₹4,572.4 crore with a margin of 26.9%, and profit after tax reached ₹1,362 crore. The company concluded FY26 with no gross debt and improved working capital efficiency, positioning it well for future investments across its diverse businesses.